Fosun Pharma adjusts fund holdings, closes 2022 stock issuance projects

Shanghai Fosun Pharmaceutical Group (Fosun Pharma) has announced a significant adjustment to its private equity investment fund, established in May 2020 to focus on early-stage innovative healthcare enterprises. The total committed capital of the fund remains unchanged at RMB 100,000万元. The adjustment involves a transfer of RMB 6,000万元 in partnership interest from Wu Zhong Guidance Fund Center to Wu Zhong Guidance Fund Company and a transfer of RMB 34,000万元 from Ningbo Fuying to Fosun Pharma Industry, both subsidiaries. Fosun Pharma's total committed capital in the fund remains at 35%.

Concurrently, Fosun Pharma also announced the successful conclusion of its 2022 non-public stock issuance fundraising projects. As of December 22, 2025, the total raised capital of RMB 445,619.87万元, including interest income, has been fully deployed across the committed investment projects: clinical development of innovative drugs, an integrated API and formulation base, and supplementary working capital. All associated special accounts have been closed, signifying the project's completion without requiring further board or shareholder approval.

Fosun Pharma will host an investor briefing on December 30, 2025, to discuss these external investment matters.